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abine Bleiziffer, MD, Hendrik Ruge, MD, Jürgen Hörer, MD, Andrea Hutter, MD,
arah Geisbüsch, MD, Gernot Brockmann, MD, Domenico Mazzitelli, MD,
obert Bauernschmitt, MD, PHD, Rüdiger Lange, MD, PHD
unich, Germany
bjectives The aim of this study was to identify risk factors for new-onset atrioventricular (AV)
lock requiring pacemaker (PM) implantation after transcatheter aortic valve implantation (TAVI).
ackground High-grade AV block and consecutive PM implantation are frequent complications fol-
owing TAVI.
ethods For logistic regression analysis, we included 159 patients (mean age: 81  6 years, EuroSCORE:
2  13%) who underwent TAVI (n  116 transfemoral, n  4 via subclavian artery, n  37 transapical,
 2 transaortic) between June 2007 and January 2009 and who had no previously implanted PM.
esults Thirty-ﬁve patients (22%) developed new-onset post-operative AV block with the need of
M implantation. Logistic regression revealed a 2-fold increased risk for new-onset AV block in pa-
ients in whom a large valve is implanted in a small annulus (32% pacemaker implantations, odds
atio [OR]: 2.378, p  NS), a 4-fold increased risk with the implantation of the CoreValve (Medtronic,
inneapolis, Minnesota) versus the Edwards Sapien valve (Edwards Lifesciences, Irvine, California)
27% pacemaker implantations, OR: 3.781, p  NS), and a 5-fold increased risk for patients who ex-
ibit an AV block episode instantly during the implantation procedure (49% pacemaker implanta-
ions, OR: 4.819, p  0.001). Pre-existing ECG alterations were not identiﬁed as risk factors for AV
lock after transcatheter aortic valve implantation.
onclusions We assume that conduction tissue impairment is provoked by mechanical compres-
ion with large prostheses in smaller annuli or in the larger area of the CoreValve covering the out-
ow tract and may appear instantly during the implantation procedure. Continuous post-operative
lectrocardiogram monitoring should be performed for at least 3 days in all patients after TAVI pro-
edures and until discharge in patients with increased risk for this complication. (J Am Coll Cardiol
ntv 2010;3:524–30) © 2010 by the American College of Cardiology Foundation
rom the Clinic for Cardiovascular Surgery, German Heart Center Munich, Munich, Germany. Drs. Bauernschmitt and
azzitelli are proctors for Edwards Lifesciences.anuscript received November 5, 2009, accepted January 24, 2010.
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525ranscatheter aortic valve implantation (TAVI) is a novel
herapeutic option for high-risk patients with aortic steno-
is. Avoiding sternotomy and cardiopulmonary bypass, this
pproach is assumed to reduce perioperative morbidity and
ortality as compared to conventional surgical aortic valve
eplacement. However, results from randomized studies are
ot currently available. Technical feasibility has been proven
y several groups (1–4), though the incidence and manage-
ent of procedure-related complications remain fields of
urrent investigation. As opposed to surgical valve replace-
ent with excision of the native aortic valve, the calcified
asses remain in situ during catheter-based aortic valve
mplantation. It is speculated that these masses affect the
onduction system in the area of the membranous septum
fter prosthesis deployment. Based on our observation that
acemaker implantation is a frequent sequela after TAVI,
he aim of the present study was to identify risk factors
redicting post-operative atrioventricular (AV) block.
ethods
atients. Between June 2007 and January 2009, 200 elderly
atients75 years of age underwent TAVI for symptomatic
igh-grade aortic stenosis at our institution. Those patients
ere refused for surgical aortic valve replacement due to
igh surgical risk. Surgical risk was assessed by the Euro-
CORE (expected mortality 20%) and clinical judgment,
f risk factors were present, which are not covered by the
core (such as repeated previous cardiac surgery, liver cir-
hosis, porcelain aorta, immobility due to orthopedic dis-
ases, etc.). All patients signed an informed consent.
wenty-six patients who had a previously implanted per-
anent pacemaker and 3 patients in whom catheter valve
mplantation was unsuccessful were excluded from the
tudy. Another 12 patients who died 14 days after
mplantation and did not undergo pacemaker implantation
ere excluded, because the end point of the present inves-
igation was pacemaker implantation within 14 days. Of
59 patients, the valve prosthesis was implanted via the
emoral artery in 116 patients (n  112 CoreValve
Medtronic, Minneapolis, Minnesota], n  4 Edwards
apien [Edwards Lifesciences, Irvine, California]), via the
eft ventricular apex in 37 patients (n  5 CoreValve, n 
2 Edwards Sapien), via the subclavian artery in 4 patients
CoreValve), and via the ascending aorta in 2 patients
CoreValve).
rostheses. Both the CoreValve prosthesis and the Ed-
ards Sapien prosthesis were implanted in our series. Both
eceived the CE mark in 2007 for transarterial implantation.
n addition, the Edwards Sapien prosthesis received the CE
ark for transapical implantation in December 2007. The
oreValve prosthesis is a porcine pericardial valve mounted
n a self-expandable nitinol stent. Transapical implantation
f the CoreValve prosthesis was performed within the gontext of the approval study (n  5, approved by the
nstitutional ethics committee). The Edwards Sapien pros-
hesis is a bovine pericardial valve in a balloon-expandable
teel stent. It is suitable for native annulus sizes of 17 to 25
m, whereas the CoreValve prosthesis can be implanted in
nnuli of 19 to 27 mm.
mplantation techniques. All patients were operated on in a
urgical hybrid suite. We opted to perform the procedures
nder general anesthesia to ensure stable hemodynamics
nd avoid patient movements during valve implantation.
ransfemoral valve implantation was performed by percu-
aneous punctuation and device closure (ProStar XL, Ab-
ott Vascular, Illinois) or by surgical dissection of the
emoral artery. For the subclavian access, the vessel was
issected through a 5-cm subclavicular skin incision (5).
ntegrade transapical aortic valve implantation was per-
ormed through a left anterolateral minithoracotomy. In 2
o-access patients, the prosthesis was implanted through
he ascending aorta with an upper ministernotomy (6). A
ransient pacemaker wire was placed transvenously for
ransarterial retrograde implantation and epicardially for
ransapical antegrade valve implantation. A balloon valvu-
oplasty of the stenotic aortic valve was performed under
apid ventricular pacing with
60 to 180 beats/min in all pa-
ients. Under fluoroscopy con-
rol, the prosthesis, crimped on
he delivery catheter, was placed
n the aortic annulus. The Core-
alve prosthesis was then re-
eased stepwise on the beating
eart, whereas the Edwards Sapien prosthesis was deployed
y balloon inflation under rapid ventricular pacing. Details
f the implantation procedures have previously been de-
cribed (1,3,5–8). Prosthesis function was assessed by an-
iography and intraoperative transesophageal echocardio-
raphic investigation. After the procedure, the patients were
ransferred to the intensive care unit and usually extubated
ithin 2 to 4 h. The transient pacemaker wire was left in
lace for at least 3 days in all patients.
ata collection and statistical analysis. The end point of the
resent study was a newly developed AV block after TAVI
equiring pacemaker implantation within 14 days after the
rocedure, according to the guidelines for reporting mor-
idity and mortality after cardiac valve interventions (9).
radyarrhythmia and sick sinus syndrome represent pre-
xisting indications for pacemaker implantation that might
ot have been noticed before aortic valve implantation and
re not related to the transcatheter valve procedure. There-
ore, our analysis targets only the patients who exhibited
ew-onset AV block requiring pacemaker implantation
ithin 14 days. An institutional database for transcatheter
alve procedures was instituted to record patients’ demo-
Abbreviations
and Acronyms
AV  atrioventricular
ECG  electrocardiogram
TAVI  transcatheter aortic
valve implantationraphics and pre-, intra-, and post-operative data.
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526Annulus diameter measurements were averaged from
omputed tomography and transthoracic and transesopha-
eal echocardiographic data, where annulus dimensions
ere measured at the level of the leaflet hinges as described
y Roman et al. (10). A borderline annulus size for valve size
as defined as an annulus of 19.5 mm for the 26-mm
oreValve, 23.5 mm for the 29-mm CoreValve, 17.5
m for the 23-mm Edwards Sapien, and21.5 mm for the
6-mm Edwards Sapien prosthesis. The presence of bulky
alcifications was assessed by echocardiography. The pre-
perative valve orifice area was obtained echocardiographi-
ally by using the continuity equation (11). Any intraoper-
tive episode of transient or persistent AV block requiring
acemaker stimulation with the transient pacemaker wires
as recorded.
The implantation height of the final prostheses place-
ent was measured in 82 patients in a fluoroscopic aorto-
ram with the deployed catheter valve in a right anterior
blique projection that displayed the aortic valve in optimal
lignment with all 3 leaflets visible en face. The depth of
elivery was defined as the distance from the native aortic
nnular margin on the side of the noncoronary cusp (left-
ard on the described projection) and on the side of the left
oronary cusp (rightward on the described projection) to the
ost proximal edge (deepest in the left ventricle) of the
eployed prosthesis stent frame. To compensate for projec-
ion errors, the depth of the prosthesis is presented in
elation to full prosthesis length. Implantation height mea-
urement is depicted in Figure 1. Due to the different
esigns, the CoreValve and the Edwards Sapien implanta-
ion heights were analyzed separately.
Descriptive data for continuous variables are presented as
ean SD or as medians with ranges. Categorical variables
Figure 1. Implantation Height Measurement
The depth of delivery of the catheter valve was deﬁned as the distance from t
on the described projection) and on the side of the left coronary cusp (c: righ
ventricle) of the deployed prosthesis stent frame. To compensate for projectio
length (b and d). Mean implantation height was deﬁned as: (a/b  c/d)/2.re presented as relative frequencies. Fisher exact test was
erformed to detect significant differences between groups.
or comparison of continuous variables between 2 groups,
he t test was used (2-tailed tests were used for all analyses).
Sixteen pre-operative and intraoperative factors were
ested for a potential impact on post-operative AV block:
ender, age, logistic EuroSCORE value, pre-operative
hythm, pre-operative AV block or right or left bundle
ranch block, pre-operative valve orifice area, aortic annulus
iameter, implanted valve type and size, borderline annulus
ize for valve size, size of valvuloplasty balloon, the differ-
nce between annulus size and valve size, the difference
etween annulus size and balloon size, the presence of bulky
alcifications, and the occurrence of intraoperative AV
lock. Variables with p values 0.1 in univariate analysis
ere entered into the multivariate model. Multivariate
nalyses were performed by means of a logistic regression
odel. Analyses were performed with SPSS version 16.0 for
indows (SPSS Inc., Chicago, Illinois).
Due to an inadequate number of measurements, the
mplantation height was analyzed separately from the mul-
ivariate analysis.
esults
f 159 patients who had no previously implanted pace-
aker, 44 required permanent pacemaker implantation
ithin 14 days after transcatheter aortic valve implantation
mean time to implantation was 4.2  3.5 days, range 0 to
1 days). Indications for pacemaker implantation were
ew-onset high-grade AV block (n  35), sick sinus
yndrome (n 1), and bradyarrhythmia (n 8). Univariate
ndings of potential influencing factors for post-operative
tive aortic annular margin on the side of the noncoronary cusp (a: leftward
on the described projection) to the most proximal edge (deepest in the left
rs, the depth of the prosthesis is presented in relation to full prosthesishe na
tward
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527V block and consecutive pacemaker requirement are sum-
arized in Table 1.
Six parameters with p  0.1 (intraoperative AV block,
alve type, borderline annulus size, pre-procedural right
undle branch block, annulus-to-balloon size difference, and
alvuloplasty balloon size) were included into the multivariate
nalysis. Logistic regression revealed intraoperative episodes of
V block requiring transient or permanent stimulation as the
nly highly significant parameter to predict later requirement
or permanent pacemaker implantation for AV block with an
dds ratio of 4.8. The implantation of a CoreValve versus an
dwards Sapien prosthesis and a borderline annulus size for
rosthesis size had a considerable effect on new-onset AV
lock, though not statistically significant on a 5% level. The
esults of the logistic regression are displayed in Table 2.
mplantation height. Due to the differing designs of the
oreValve and the Edwards Sapien prosthesis, implantation
eight was analyzed separately for the 2 groups. The mean
epth of the CoreValve prosthesis in the left ventricular
Table 1. Univariate Analysis
Parameter
All Patients
(n  159)
Female sex 91 (57%)
Mean age, yrs 80.8 6.2
Mean logistic EuroSCORE, % 21.6 13.0
Pre- and intraoperative ECG ﬁndings
Pre-operative heart rhythm
Sinusal 114 (73%)
Atrial ﬁbrillation 41 (26%)
Supraventricular rhythm 1 (1%)
Pre-operative AV block °I 22 (14%)
Pre-operative right bundle branch block 6 (4%)
Pre-operative left bundle branch block 27 (17%)
Intraoperative AV block 37 (23%)
Prosthesis and balloon-speciﬁc parameters
Valve type
CoreValve 124 (78%)
Edwards Sapien 35 (22%)
Labeled valve size
23 mm 13 (8%)
26 mm 65 (41%)
29 mm 81 (51%)
Valvuloplasty balloon size, mm 23.0 2.1
Anatomic parameters
Pre-operative valve oriﬁce area 0.65 0.2
Annulus diameter, mm 22.8 2.0
Borderline annulus size for valve size 41 (26%)
Annulus-to-valve size difference (annulus diameter
minus labeled valve size), mm
–4.5 1.4
Annulus-to-balloon size difference, mm –0.13 1.6
Bulky calciﬁcations 25 (16%)
AV atrioventricular; ECG electrocardiogram.utflow tract was 23  11% of full prosthesis length in 70nvestigated angiograms, that is, 12  6 mm of the stent
rame are localized below the native aortic annulus. There
as a tendency for deeper prosthesis implantation in pa-
ients who needed post-procedural pacemaker implantation.
mplantation depth was 20  9% (n  41, no AV block)
ersus 24  13% (n  29, new-onset AV block) at the
Patients Without
V Block (n  124)
Patients With
New-Onset AV Block (n  35) p Value
69 (56%) 22 (63%) 0.446
80.7 6.4 81.2 5.8 0.648
21.6 13.1 21.7 12.9 0.967
0.869
89 (72%) 25 (71%)
32 (26%) 9 (26%)
1 (1%) 0
15 (12%) 7 (20%) 0.232
3 (2%) 3 (9%) 0.078
20 (16%) 7 (20%) 0.504
19 (15%) 18 (51%) 0.000
91 (73%) 33 (94%) 0.008
33 (27%) 2 (6%)
12 (10%) 1 (3%) 0.297
52 (42%) 13 (37%)
60 (48%) 21 (60%)
22.8 2.1 23.7 1.8 0.019
0.65 0.2 0.65 0.2 0.928
22.8 2.1 22.9 1.8 0.841
28 (23%) 13 (37%) 0.069
–4.4 1.4 –4.8 1.5 0.133
–0.01 1.5 –0.65 1.6 0.045
22 (18%) 3 (9%) 0.188
Table 2. Results of the Logistic Regression
Parameter
Univariate
p Value
Multivariate
p Value
Odds
Ratio 95% CI
Intraoperative AV block 0.000 0.001 4.819 2.0–11.9
Valve type  CoreValve 0.008 0.090 3.781 0.8–17.6
Borderline annulus size for
valve size
0.069 0.063 2.378 1.0–5.9
Valvuloplasty balloon size 0.019
Right bundle branch block 0.078
Annulus-to-balloon size
difference
0.045ACI confidence interval; other abbreviation as in Table 1.
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528oncoronary cusp (p  0.150), 22  11% versus 27  19%
t the left-coronary cusp (p  0.169), and mean implanta-
ion depth was 21  9% versus 26  13% (p  0.104),
espectively. Edwards Sapien mean implantation height was
7  17%, 27  18% at the noncoronary cusp, and 26 
7% at the left coronary cusp (n  12). As only 1 of 12
atients required post-procedural pacemaker implantation,
o statistics were performed for this group.
iscussion
he TAVI procedure is a novel treatment option for
onsurgical patients with severe symptomatic aortic ste-
osis. The nature and incidence of complications after
ranscatheter treatment of aortic stenosis are different
han those after conventional surgical aortic valve re-
lacement. A high incidence of post-procedural pace-
aker implantation is 1 of the sequelae requiring partic-
lar consideration in this context.
Few series of 10 to 102 patients describe new pacemaker
mplantation in 27% to 33% of the patients after CoreValve
mplantation (12–14), and in 4% to 12% after Edwards
apien implantation (15,16). In our series of 200 patients,
he overall incidence of new pacemaker implantation within
4 days was 22% (n  44). However, it was crucial to
liminate patients from the analysis who died 14 days
fter prosthesis implantation (n 12), patients in whom the
rosthesis implantation procedure was not successful (n 
), and patients who had a previously implanted pacemaker
n  26) to report the factual pacemaker implantation rate
f 28% (44 of 159) only in patients who are at risk for this
omplication. The overall new pacemaker implantation rate
f the series described might under-report the actual rate of
acemaker requirement. We additionally separated the pa-
ients who developed new-onset AV block, which is a
rocedure associated complication, from those who appar-
ntly had pre-existing indications for pacemaker implanta-
ion, such as bradyarrhythmia or sick sinus syndrome.
herefore, we state that the rate of procedure-associated
acemaker requirement was 22% (35 of 159) in our series,
hich is significantly higher than the reported rates of up to
% after conventional surgical aortic valve replacement
17–19).
Pacemaker implantation was performed according to the
uropean Society of Cardiology guidelines for cardiac
acing and cardiac resynchronization therapy (20). When
he bradyarrhythmias were diagnosed during the post-
perative monitoring, pacemaker implantation was per-
ormed without further hesitation even in cases of intermit-
ent bradyarrhythmias. This approach might be called a
omewhat liberal indication, but in this population of elderly
atients all with underlying organic heart disease, we opted
or patients’ safety. IAs sudden post-operative AV block can be a life-
hreatening complication, we aimed to detect risk factors
redicting this complication to identify patients with the
eed for prolonged electrocardiogram (ECG) monitoring.
wo patients in our series with sudden unexplained in-
ospital death might have developed an unrecognized AV
lock. One of those had a borderline annulus size for valve
ize, which has been identified as a risk factor for AV block
y multivariate analysis.
Reasons for post-operative AV block after surgical aortic
alve replacement are injury to the cardiac conduction
ystem during surgical excision of the adjacent diseased
alve and annular tissue. It is speculated that conduction
issue injury during TAVI is induced by mechanical pressure
o the conduction system by the prosthesis and the native
alve calcium that remains in situ. Subsequently edema,
schemia, and necrosis may develop. Therefore, we looked at
arameters associated with the induced dilating pressure,
hich may affect the conduction system during TAVI. The
alvuloplasty balloon size used and the difference between
he balloon size and the aortic annulus were found to be
ignificantly larger in patients who developed AV block
p  0.019 and p  0.045, respectively). However, both
arameters were not found to influence pacemaker require-
ent by multivariate analysis.
The presence of bulky calcifications assessed echocardio-
raphically did not predict the development of AV block.
dditionally, preliminary results from 3-dimensional mea-
urements of the native valve calcium volume in 27 pre-
perative computed tomography scans revealed no associa-
ion between native valve calcium volume and the
ccurrence of AV block. However, a recent study demon-
trated the noncoronary cusp thickness measured by trans-
sophageal echocardiography as being a predictive parame-
er for the need for pacemaker implantation, indicating that
n AV block may be predicted by pre-operative imaging
21).
Concerning the size of the implanted prosthesis in
elation to the native annulus size, we found that patients
ith an annulus at the lower edge of the recommended size
or a specific prosthesis size (an annulus of 19.5 mm for
he 26-mm CoreValve, 23.5 mm for the 29-mm Core-
alve, 17.5 mm for the 23-mm Edwards Sapien, and
21.5 mm for the 26-mm Edwards Sapien prosthesis)
xhibited an increased risk for pacemaker implantation
32% [13 of 41] pacemaker implantation, p  0.069). Such
borderline relation between annulus size and prosthesis
ize was detected to more than double the risk for pace-
aker requirement in the logistic regression analysis (odds
atio [OR]: 2.378, not significant on the 5% level, p 
.063). However, we opted for the larger valve size when the
ize of the aortic annulus was in between 2 valve sizes to
inimize the risk of valve migration and paravalvular leak.n summary, these data support the hypothesis that in-
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529reased pressure to the conduction system by relatively
arger valvuloplasty balloons or larger prostheses in a smaller
nnulus increases the risk of new-onset AV block.
There is an ongoing discussion to which extent pre-
xisting ECG alterations influence the occurrence of new-
nset AV block after TAVI (21–23). In our series, a
re-existing AV block grade I and a pre-existing left bundle
ranch block were not risk factors for new-onset high-grade
V block after the transcatheter valve procedures. Jilaihawi
t al. (21) identified left axis deviation and left bundle
ranch block with left axis deviation as strong predictors for
ermanent pacemaker requirement, but not left bundle
ranch block alone. In contrast, of the patients with
re-existing right bundle branch block, 50% (3 of 6, p 
.078) experienced procedure-related high-grade AV block.
owever, right bundle branch block was rare in our series,
nd this parameter was not relevant by multivariate analysis.
n concordance with our findings, Sinhal et al. (23) found
o statistically significant association between pre-existing
CG alterations and new-onset AV block. Piazza et al. (22)
peculate that a pre-existing right bundle branch block
ight be a strong predictor for later pacemaker require-
ent, as both (2 of 2) patients with right bundle branch
lock in their series of 40 patients developed AV block.
ccording to Koplan et al. (24), right bundle branch block
s a strong predictor of pacemaker requirement in patients
ndergoing conventional valve surgery. As right bundle
ranch block is an infrequent phenomenon, very large
opulations have to be investigated to reveal a potentially
ignificant effect.
Our data give evidence that patients who undergo cath-
ter valve implantation with the CoreValve prosthesis are at
igher risk for post-operative AV block. Among 124 pa-
ients receiving a CoreValve prosthesis, 27% underwent
acemaker implantation for valve-related AV block, com-
ared with 6% of 35 patients who received an Edwards
apien prosthesis (p  0.008). Multivariate analysis re-
ealed an almost 4-fold increased risk for AV block with the
oreValve prosthesis (not significant on the 5% level, p 
.090). This is the first description of this phenomenon, as
ost of the other centers implant either the CoreValve or
he Sapien prosthesis. There was a tendency toward lower
oreValve position within the left ventricular outflow tract
n patients developing post-operative AV block, though this
endency was not significant. In the study by Piazza et al.
22), a low CoreValve position was associated with the
evelopment of new-onset left bundle branch block. It is
peculated that with a low CoreValve position in the left
entricular outflow tract there is a larger stent frame area
hat potentially compresses the conduction system.
The most evident finding from this study is that patients
ho experience an AV block instantly in the operating room
fter balloon valvuloplasty or after valve deployment exhibit
n almost 5-fold risk to develop permanent AV block withhe need for pacemaker implantation by logistic regression
nalysis. This finding was highly significant (p  0.001).
mong patients with intraoperative AV block, 49% (18 of
7) required later pacemaker implantation as opposed to
nly 14% (17 of 122) in patients without intraoperative AV
lock. We assume that conduction tissue injury may imme-
iately be caused by compression from the balloon or the
rosthesis. In those patients, post-procedural ECG moni-
oring should be extended to at least 5 days.
In summary, valve-related AV block requiring pacemaker
mplantation is a frequent finding after TAVI that occurred
n 22% in our series. Our data demonstrate a 2-fold
ncreased risk for new-onset AV block in patients in whom
large valve is implanted in a small annulus (OR: 2.378,
 NS), a 4-fold increased risk with the implantation of
he CoreValve versus the Edwards Sapien valve (OR: 3.781,
 NS), and a 5-fold increased risk for patients who
xhibit an AV block episode instantly during the implanta-
ion procedure (p  0.001). We assume that conduction
issue impairment is provoked by mechanical compression
ith relatively large balloons and prostheses in smaller
nnuli and may appear instantly during the implantation
rocedure. However, the implantation of large prostheses in
maller annuli cannot be avoided without increasing the risk
or paravalvular leakage. Continuous post-operative ECG
onitoring should be performed for at least 3 days in all
atients, and until discharge in patients with increased risk
or this complication. In this population of elderly patients,
ll with underlying organic heart disease, we opted for
atients’ safety and did not hesitate to implant a pacemaker,
f episodes of high-grade AV block were diagnosed during
he post-operative course.
eprint requests and correspondence: Dr. Sabine Bleiziffer,
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